58th European Association for the Study of Diabetes (EASD) Annual Meeting

ESSENTIAL: Ezetimibe plus statin reduces liver fat

Elvira Manzano, 20221031000000

Ezetimibe plus rosuvastatin reduces liver fat in people with nonalcoholic fatty liver disease (NAFLD) in the randomized, active-controlled ESSENTIAL trial.

Hysterectomy tied to increased diabetes risk

Roshini Claire Anthony, 20221021180001

Undergoing a hysterectomy, particularly at a young age, may be associated with an increased risk of developing diabetes, according to a study from France presented at EASD 2022.

Beta-blocker shows potential for diabetic foot ulcers

Audrey Abella, 20221020100000

A novel, topical formulation of esmolol, a cardio-selective beta-1 adrenergic blocker, may just have landed a spot in the diabetes treatment landscape, as it shows promise as treatment alternative for diabetic foot ulcers (DFUs).

Sotagliflozin may offer cardiorenal protection for adults with T1D

Audrey Abella, 20221013100000

Using the Steno T1 Risk Engines, the dual SGLT*1 and SGLT2 inhibitor sotagliflozin showed potential in reducing the risk of cardiovascular (CV) and renal disease in adults with type 1 diabetes (T1D).

Triple-drug combo reduces HbA1c in T2D

Elaine Soliven, 20221012000000

Adding evogliptin, a novel dipeptidyl peptidase-4 inhibitor, to dapagliflozin and metformin significantly reduced HbA_1c level in patients with uncontrolled type 2 diabetes (T2D), according to a study presented at EASD 2022.

Young age at diabetes diagnosis tied to worse outcomes

Does age at diagnosis affect diabetes outcomes?

Roshini Claire Anthony, 20221009110001

Individuals who are diagnosed with type 2 diabetes (T2D) at age ≤40 years have a greater risk of cardiovascular disease (CVD) and mortality than same-aged individuals without T2D or individuals diagnosed with T2D in later life, according to a study from Korea presented at EASD 2022.

Tirzepatide confers renal protection in patients with T2D

Elaine Soliven, 20221005000000

Once-weekly injection of tirzepatide, a dual GIP and GLP-1 receptor antagonist, slowed eGFR* decline and reduced UACR** in patients with type 2 diabetes (T2D) who are at high risk of cardiovascular (CV) disease compared with once-daily insulin glargine (iGlar), according to a prespecified post hoc analysis of the SURPASS-4*** trial presented at EASD 2022.